What Are the Long-Term Side Effects of Semaglutide?

The side effects that tend to linger, and why most of them do settle

Semaglutide slows gastric emptying, which is central to how it reduces appetite. That same mechanism is also behind the GI effects that trouble some people for longer than the first few weeks. If you want a thorough rundown before you begin, our dedicated page covering what side effects to expect from semaglutide walks through each of them in detail. Nausea is the most reported. For many, it peaks around the time a new dose is introduced and fades within a fortnight. For some, it never fully disappears, particularly at the 2.4mg maintenance level.

Constipation, loose stools, reflux and belching are all documented in the trial data. The NHS patient information on semaglutide lists these clearly, and they're worth reading in full before you start. The practical reality many people find is that symptom burden is greatest in the titration phase and often improves once the body adjusts. Eating smaller portions, chewing slowly and avoiding very fatty meals can reduce the severity, our prescribers cover this during aftercare.

Fatigue and headaches are also reported, particularly in the early months. These tend not to be a feature of treatment after the first few dose changes. What matters for a long-term perspective is monitoring whether symptoms change at each stage, not just at the beginning. If something new appears months into treatment, that warrants a conversation rather than waiting it out. The full picture of Wegovy's side effect profile covers more of these patterns in practical terms.

Rare but serious: what to watch for over time

Two serious risks are worth naming plainly. The first is acute pancreatitis. It's uncommon, but the MHRA flagged it formally in a Drug Safety Update in January 2026 because the signal in GLP-1 medicines is real. The warning sign is severe stomach pain that comes on suddenly and radiates through to the back, sometimes with vomiting. This is not ordinary nausea. It needs urgent medical attention, not a wait-and-see approach.

The second is gallbladder disease. Rapid weight loss of any kind increases the likelihood of gallstones, and semaglutide trials recorded gallbladder-related events at rates above placebo. People with a history of gallbladder problems should discuss this specifically with their prescriber before starting. You can read more about how semaglutide interacts with existing health conditions on our page about semaglutide safety for people without diabetes.

Diabetic retinopathy is another consideration raised in trials, primarily in people with type 2 diabetes who had pre-existing eye disease. The mechanism isn't fully understood. For people using semaglutide for weight management without diabetes, this risk appears much lower, but it's still part of the prescriber's assessment. Heart rate: semaglutide can cause a small increase in resting heart rate. For most people this has no clinical significance, but it's monitored in people with existing cardiac conditions.

It's also worth knowing that the longest-running trial data for semaglutide 2.4mg covers around 68 weeks. That's meaningful but not a decade. Ongoing surveillance, including via the Yellow Card scheme, is part of how the safety picture grows. If you're thinking about committing to treatment for years rather than months, our page on what the long-term side effects of Wegovy may look like brings together what's currently known from post-approval monitoring.

When to get medical help, and when not to dismiss something as 'just a side effect'

Some things should prompt same-day or emergency care. Severe, sudden abdominal pain that reaches your back is one of them. Signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing) are another. Symptoms of severe dehydration from persistent vomiting or diarrhoea, such as dizziness on standing and dark urine, need prompt attention rather than riding out.

Low mood and changes in mental health are listed in the product information. If you notice new or worsening depression, or any thoughts of self-harm, stop the medicine and speak to your GP or call 111 immediately. This is in the leaflet for a reason.

On the non-urgent side: if nausea is making it hard to eat or drink normally, tell your prescriber before the next scheduled dose rather than after. If your injection site is consistently sore or inflamed, it's usually a technique issue worth sorting early. You can check injection technique guidance and other practical questions in our FAQs. And if you're unsure whether something you're experiencing is expected, our aftercare team is available seven days a week.

Every pen should be stored in the fridge (many people keep it in the fridge door alongside everyday items so it stays visible) and the Patient Information Leaflet that comes with each pen sets out the exact room-temperature window for travel or days away from home. Follow it, rather than guessing.

How these risks weigh against the benefits, what a prescriber is actually assessing

None of this should read as a reason to avoid semaglutide. The STEP 1 trial, published in the New England Journal of Medicine, found average weight reductions of around 15% over 68 weeks at the 2.4mg dose, alongside meaningful improvements in blood pressure, blood sugar and lipid profiles. The question isn't whether there are side effects (there are) but whether their profile is reasonable given someone's starting health picture.

That's precisely the calculation a prescriber is making: your BMI, your existing conditions, your current medicines, your history. It's not a generic risk-benefit. It's yours specifically. The side effects of Wegovy page covers how those risks change at different dose levels, which is relevant to anyone titrating upward over time.

People who are pregnant, breastfeeding or trying to conceive should not use semaglutide; the medicine is also not licensed for use under 18. Women using hormonal contraception should be aware of the potential for reduced pill absorption during titration and discuss this with their prescriber. For a broader look at who the treatment suits and how the consultation at our weight loss service works, our clinical team page gives a sense of who is reviewing your answers. You can also read more about Wegovy as a treatment including how the licensed programme is structured in the UK.